These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 27580554)

  • 1. A Cluster Headache Responsive to Ramelteon, a Selective Melatonin MT1/MT2 Receptor Agonist.
    Imai N
    Intern Med; 2016; 55(17):2483-5. PubMed ID: 27580554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A novel therapeutic drug: ramelteon].
    Miyamoto M
    Nihon Rinsho; 2009 Aug; 67(8):1595-600. PubMed ID: 19768947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Case of Unilateral Hypnic Headache: Rapid Response to Ramelteon, a Selective Melatonin MT1/MT2 Receptor Agonist.
    Arai M
    Headache; 2015; 55(7):1010-1. PubMed ID: 26121162
    [No Abstract]   [Full Text] [Related]  

  • 4. Ramelteon 8 mg/d versus placebo in patients with chronic insomnia: post hoc analysis of a 5-week trial using 50% or greater reduction in latency to persistent sleep as a measure of treatment effect.
    Mini L; Wang-Weigand S; Zhang J
    Clin Ther; 2008 Jul; 30(7):1316-23. PubMed ID: 18691991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ramelteon: TAK 375.
    Drugs R D; 2005; 6(3):186-8. PubMed ID: 15869323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoimmune hepatitis in association with ramelteon.
    Fourman LT; Robert Meyer B
    J Clin Gastroenterol; 2013 Aug; 47(7):651-4. PubMed ID: 23632362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ramelteon: a melatonin receptor agonist for the treatment of insomnia.
    Devi V; Shankar PK
    J Postgrad Med; 2008; 54(1):45-8. PubMed ID: 18296808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist.
    Kato K; Hirai K; Nishiyama K; Uchikawa O; Fukatsu K; Ohkawa S; Kawamata Y; Hinuma S; Miyamoto M
    Neuropharmacology; 2005 Feb; 48(2):301-10. PubMed ID: 15695169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ramelteon and improved insomnia in alcohol-dependent patients: a case series.
    Brower KJ; Conroy DA; Kurth ME; Anderson BJ; Stein MD
    J Clin Sleep Med; 2011 Jun; 7(3):274-5. PubMed ID: 21677897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fresh from the pipeline: Ramelteon.
    Buysse D; Bate G; Kirkpatrick P
    Nat Rev Drug Discov; 2005 Nov; 4(11):881-2. PubMed ID: 16299918
    [No Abstract]   [Full Text] [Related]  

  • 11. Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty.
    Mini LJ; Wang-Weigand S; Zhang J
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):177-84. PubMed ID: 17996657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ramelteon: profile of a new sleep-promoting medication.
    Owen RT
    Drugs Today (Barc); 2006 Apr; 42(4):255-63. PubMed ID: 16703122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ramelteon, a selective MT1/MT2 receptor agonist, suppresses the proliferation and invasiveness of endometrial cancer cells.
    Osanai K; Kobayashi Y; Otsu M; Izawa T; Sakai K; Iwashita M
    Hum Cell; 2017 Jul; 30(3):209-215. PubMed ID: 28382516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of a post-sleep questionnaire-interactive voice response system (PSQ-IVRS) to evaluate the subjective sleep effects of ramelteon in adults with chronic insomnia.
    Wang-Weigand S; Watissée M; Roth T
    Sleep Med; 2011 Oct; 12(9):920-3. PubMed ID: 21925941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic evaluation of ramelteon : an insomnia therapy.
    Spadoni G; Bedini A; Lucarini S; Mor M; Rivara S
    Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1145-56. PubMed ID: 25956235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders.
    Miyamoto M
    CNS Neurosci Ther; 2009; 15(1):32-51. PubMed ID: 19228178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melatonin receptors mediate improvements of survival in a model of polymicrobial sepsis.
    Fink T; Glas M; Wolf A; Kleber A; Reus E; Wolff M; Kiefer D; Wolf B; Rensing H; Volk T; Mathes AM
    Crit Care Med; 2014 Jan; 42(1):e22-31. PubMed ID: 24145838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ramelteon: a review of its use in insomnia.
    Simpson D; Curran MP
    Drugs; 2008; 68(13):1901-19. PubMed ID: 18729542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization of M-II, the major human metabolite of ramelteon.
    Nishiyama K; Nishikawa H; Kato K; Miyamoto M; Tsukamoto T; Hirai K
    Pharmacology; 2014; 93(3-4):197-201. PubMed ID: 24923230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment.
    Roth T; Stubbs C; Walsh JK
    Sleep; 2005 Mar; 28(3):303-7. PubMed ID: 16173650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.